Home / Companies / News / DRL to launch innovator brand of favipiravir, is silent on pricing

DRL to launch innovator brand of favipiravir, is silent on pricing

Ties up with Fujifilm for exclusive rights over Avigan for Indian market, can sell overseas too

Favipiravir, Umifenovir, atniviral, drugs, pharma, coronavirus, covid-19, sars, cov-2

Premium

The company did not wish to disclose the price of the drug or by when it could launch it in the Indian market

2 min read Last Updated : Jul 01 2020 | 8:42 PM IST

The next favipiravir brand will be in market soon as Hyderabad-based Dr Reddy's Laboratories (DRL) on Wednesday said that it has tied up with the innovator Fujifilm to launch the brand Avigan in India. DRL has the rights to sell the drug overseas other than Japan, China and Russia.

The company did not wish to disclose the price of the drug or by when it could launch it in the Indian market. It would be a nod from the country's drug regulator before it can launch the product for Indian market. Mumbai based Glenmark has launched the drug for Rs 103

Topics : Coronavirus Dr Reddy’s Laboratories Pharmaceuticals COVID-19

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in